CCK-B Targeted Polyplex Nanoparticles for Pancreatic Cancer Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for pancreatic cancer, such as CT and MRI, are limited in detecting early-stage pancreatic intraepithelial neoplasia (PanIN) lesions, and existing imaging techniques fail to identify precancerous stages effectively, leading to late detection and poor prognosis.
Innovation Solution
Development of a targeted polyplex nanoparticle conjugated with a cholecystokinin-B (CCK-B) receptor ligand and a detectable moiety, which selectively binds to CCK-B receptors overexpressed in PanIN lesions, allowing for early detection and potential therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard radiographic imaging (CT, MRI) is used for pancreatic cancer detection, then the imaging techniques are widely available and non-invasive, but they can only detect tumors greater than 2 cm and miss 23% of small lesions
Solution Approach 1:
The patent uses a targeted polyplex nanoparticle as an intermediary agent that carries a detectable moiety to selectively bind to CCK-B receptors on PanIN lesions. This nanoparticle mediator enables detection of microscopic lesions that are invisible to standard CT and MRI techniques, resolving the contradiction between detection sensitivity and imaging complexity by introducing a molecular-level detection mechanism rather than relying on anatomical imaging alone.
Solution Approach 2:
The patent employs a detectable moiety (such as a fluorophore or radioactive isotope) conjugated to the nanoparticle that emits signals when bound to PanIN lesions. This allows visualization of microscopic cancerous changes through optical or radiological signals, enabling detection below the resolution threshold of conventional anatomical imaging techniques.
2Measurement precision
If endoscopic ultrasound (EUS) is used to detect pancreatic cysts, then sensitivity for cyst evaluation is high, but the overwhelming majority of cysts are benign and only 15% of cancers arise from cysts
Solution Approach 1:
The patent applies local quality by designing a nanoparticle with specific targeting capabilities that distinguish between benign cysts and precancerous PanIN lesions based on their molecular characteristics. The CCK-B receptor ligand selectively binds to receptors overexpressed in PanIN lesions, allowing differentiation between benign and malignant transformations at the molecular level rather than relying solely on structural cyst evaluation.
Solution Approach 2:
The patent replaces the mechanical ultrasound imaging system with a molecular targeting system using targeted polyplex nanoparticles. This substitution enables detection of PanIN lesions that are not visible on EUS by utilizing specific molecular interactions between the nanoparticle ligand and CCK-B receptors on the lesion surface, providing information about precancerous changes that EUS cannot detect.
3Measurement precision
If targeted polyplex nanoparticle with CCK-B receptor ligand is used, then detection of PanIN lesions is achieved, but the system complexity increases
Solution Approach 1:
The patent segments the detection system into distinct functional components: (1) the polyplex nanoparticle carrier, (2) the CCK-B receptor ligand targeting moiety, and (3) the detectable moiety. This segmentation allows each component to be optimized independently and facilitates manufacturing and regulatory approval by treating the system as modular rather than monolithic, reducing the practical complexity despite the sophisticated functionality.
Solution Approach 2:
The patent uses composite materials by combining polyethylene glycol (PEG) blocks with poly(L-lysine) blocks to form a polyplex nanoparticle. This composite structure provides both the targeting capability (through the lysine block binding to CCK-B receptors) and the detectable signal (through the PEG-conjugated detectable moiety), achieving PanIN detection while managing complexity through established materials science techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle effectively localizes to PanIN lesions in genetically engineered mouse models and human tissues, enhancing early detection capabilities and providing a potential tool for improving pancreatic cancer survival rates by identifying precancerous stages.
Implementation Method 1
a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety
Implementation Method 2
a detectable moiety complexed with, or conjugated to, the poly(L-lysine) of the polymer moiety
Data Source
AI summary
A method that includes detecting the presence of a pancreatic intraepithelial neoplasia lesion in a subject in vivo comprising administering to the subject a construct, or a pharmaceutically acceptable salt thereof, wherein the construct comprises:(a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized;(b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and(c) a detectable moiety complexed with, or conjugated to, the poly(L-lysine) of the polymer moiety,wherein the construct is neutralized.